GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » Price-to-Free-Cash-Flow

Dynavax Technologies (LTS:0IDA) Price-to-Free-Cash-Flow : 22.58 (As of May. 10, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies Price-to-Free-Cash-Flow?

As of today (2025-05-10), Dynavax Technologies's share price is $9.505. Dynavax Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.42. Hence, Dynavax Technologies's Price-to-Free-Cash-Flow Ratio for today is 22.58.

The historical rank and industry rank for Dynavax Technologies's Price-to-Free-Cash-Flow or its related term are showing as below:

LTS:0IDA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.06   Med: 16.8   Max: 92.93
Current: 25.8

During the past 13 years, Dynavax Technologies's highest Price-to-Free-Cash-Flow Ratio was 92.93. The lowest was 4.06. And the median was 16.80.

LTS:0IDA's Price-to-Free-Cash-Flow is ranked better than
50.78% of 510 companies
in the Drug Manufacturers industry
Industry Median: 23.3 vs LTS:0IDA: 25.80

Dynavax Technologies's Free Cash Flow per Share for the three months ended in Dec. 2024 was $0.37. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.42.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Dynavax Technologies was 8.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -43.10% per year.

During the past 13 years, Dynavax Technologies's highest 3-Year average Free Cash Flow per Share Growth Rate was 52.90% per year. The lowest was -43.10% per year. And the median was 11.10% per year.


Dynavax Technologies Price-to-Free-Cash-Flow Historical Data

The historical data trend for Dynavax Technologies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Price-to-Free-Cash-Flow Chart

Dynavax Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 5.74 28.83 18.66 28.31

Dynavax Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.66 36.72 50.36 79.57 28.31

Competitive Comparison of Dynavax Technologies's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Price-to-Free-Cash-Flow falls into.


;
;

Dynavax Technologies Price-to-Free-Cash-Flow Calculation

Dynavax Technologies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=9.505/0.421
=22.58

Dynavax Technologies's Share Price of today is $9.505.
Dynavax Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Dynavax Technologies  (LTS:0IDA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Dynavax Technologies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 720, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Headlines

No Headlines